Synopsis
Synopsis
0
CEP/COS
0
JDMF
0
KDMF
0
VMF
0
Canada
0
Australia
0
South Africa
0
Listed Dossiers
0
EDQM
0
USP
0
JP
0
Others
0
Data Compilation #PharmaFlow
0
Stock Recap #PipelineProspector
0
Weekly News Recap #Phispers
Annual Reports
NA
1. 2(s),4(s),5(s),7(s)-n-(2-carbamoyl-2-methylpropyl)-5-amino-4-hydroxy-2,7-diisopropyl-8-(4-methoxy-3-(3-methoxypropoxy)phenyl)octanamid Hemifumarate
2. Aliskiren
3. Cgp 060536b
4. Cgp-060536b
5. Cgp060536b
6. Rasilez
7. Spp100
8. Tekturna
1. 173334-58-2
2. Tekturna
3. Aliskiren Fumarate
4. Aliskiren (hemifumarate)
5. Enviage
6. Riprazo
7. Sprimeo
8. Spp-100b
9. Chebi:53777
10. C8a0p8g029
11. Nsc-759185
12. Cgp 60536
13. Aliskirenfumarate
14. (2s,4s,5s,7s)-5-amino-n-(3-amino-2,2-dimethyl-3-oxopropyl)-4-hydroxy-7-[[4-methoxy-3-(3-methoxypropoxy)phenyl]methyl]-8-methyl-2-propan-2-ylnonanamide;(e)-but-2-enedioic Acid
15. Cgp60536b
16. Bis(2s,4s,5s,7s)-5-amino-n-(3-amino-2,2-dimethyl-3-oxopropyl)-4-hydroxy-7-(4-methoxy-3-(3-methoxypropoxy)benzyl)-8-methyl-2-(1-methylethyl)nonanamide) (2e)-but-2-enedioate
17. Aliskiren Fumarate [usan]
18. Unii-c8a0p8g029
19. Aliskiren Fumarate [usan:jan]
20. Tekturna (tn)
21. Cgp-60536
22. Aliskiren Hemifumarate- Bio-x
23. Schembl187762
24. Aliskiren (as Fumarate)
25. Aliskiren Fumarate (jan/usan)
26. Aliskiren Fumarate [jan]
27. Chembl3545059
28. Cgp-60536b
29. Aliskiren Fumarate [mart.]
30. Aliskiren Hemifumarate [mi]
31. Aliskiren Fumarate [who-dd]
32. Mfcd10566724
33. S2199
34. Aliskiren Hemifumarate [vandf]
35. Akos015896419
36. Ccg-270658
37. Cs-0729
38. Ks-1395
39. Nsc 759185
40. S12129
41. (2s,4s,5s,7s)-5-amino-n-(3-amino-2,2-dimethyl-3-oxopropyl)-4-hydroxy-2-isopropyl-7-(4-methoxy-3-(3-methoxypropoxy)benzyl)-8-methylnonanamide Hemifumarate
42. Ba164146
43. Hy-12177
44. Aliskiren Hemifumarate [orange Book]
45. Sw222231-1
46. D06412
47. Rasitrio Component Aliskiren Hemifumarate
48. Tekamlo Component Aliskiren Hemifumarate
49. Valturna Component Aliskiren Hemifumarate
50. Amturnide Component Aliskiren Hemifumarate
51. Rasilamlo Component Aliskiren Hemifumarate
52. Aliskiren Hemifumarate Component Of Rasitrio
53. Aliskiren Hemifumarate Component Of Tekamlo
54. Aliskiren Hemifumarate Component Of Valturna
55. Raprazo-hct Component Aliskiren Hemifumarate
56. Rasilez-hct Component Aliskiren Hemifumarate
57. Sprimeo-hct Component Aliskiren Hemifumarate
58. Aliskiren Hemifumarate Component Of Amturnide
59. Aliskiren Hemifumarate Component Of Rasilamlo
60. Tekturna Hct Component Aliskiren Hemifumarate
61. Aliskiren Hemifumarate Component Of Raprazo-hct
62. Aliskiren Hemifumarate Component Of Rasilez-hct
63. Aliskiren Hemifumarate Component Of Sprimeo-hct
64. Q27124205
65. Aliskiren Hemifumarate Component Of Tekturna Hct
66. (?s,?s,?s,?s)-?-amino-n-(3-amino-2,2-dimethyl-3-oxopropyl)-?-hydroxy-4-methoxy-3-(3-methoxypropoxy)-?,?-bis(1-methylethyl)benzeneoctanamide Hemifumarate
67. 5-amino-n-(3-amino-2,2-dime-3-oxoprop)-4-oh-2-isoprop-7-[4-meo-3-(3-meo-propoxy)benzyl]-8-methylnonanamide Hemifumarate
68. Benzeneoctanamide, Delta-amino-n-(3-amino-2,2-dimethyl-3-oxopropyl)-gamma-hydroxy-4-methoxy-3-(3-methoxypropoxy)-alpha,zeta-bis(1-methylethyl)-, (alphas,gammas,deltas,zetas)-, (2e)-2-butenedioate (2:1) (salt)
69. Bis((2s,4s,5s,7s)-5-amino-n-(3-amino-2,2-dimethyl-3-oxopropyl)-4-hydroxy-2-isopropyl-7-(4-methoxy-3-(3-methoxypropoxy)benzyl)-8-methylnonanamide) Fumarate
70. Bis{(2s,4s,5s,7s)-5-amino-n-(3-amino-2,2-dimethyl-3-oxopropyl)-4-hydroxy-7-[4-methoxy-3-(3-methoxypropoxy)benzyl]-8-methyl-2-(propan-2-yl)nonanamide} (2e)-but-2-enedioate
Molecular Weight | 1219.6 g/mol |
---|---|
Molecular Formula | C64H110N6O16 |
Hydrogen Bond Donor Count | 10 |
Hydrogen Bond Acceptor Count | 18 |
Rotatable Bond Count | 40 |
Exact Mass | 1218.79783144 g/mol |
Monoisotopic Mass | 1218.79783144 g/mol |
Topological Polar Surface Area | 367 Ų |
Heavy Atom Count | 86 |
Formal Charge | 0 |
Complexity | 836 |
Isotope Atom Count | 0 |
Defined Atom Stereocenter Count | 8 |
Undefined Atom Stereocenter Count | 0 |
Defined Bond Stereocenter Count | 1 |
Undefined Bond Stereocenter Count | 0 |
Covalently Bonded Unit Count | 3 |
1 of 2 | |
---|---|
Drug Name | Tekturna |
PubMed Health | Aliskiren (By mouth) |
Drug Classes | Antihypertensive |
Drug Label | Tekturna contains aliskiren hemifumarate, a renin inhibitor, that is provided as tablets for oral administration. Aliskiren hemifumarate is chemically described as (2S,4S,5S,7S)-N-(2-carbamoyl-2-methylpropyl)-5-amino-4-hydroxy-2,7-diisopropyl-8-[4-me... |
Active Ingredient | Aliskiren hemifumarate |
Dosage Form | Tablet |
Route | Oral |
Strength | eq 150mg base; eq 300mg base |
Market Status | Prescription |
Company | Novartis |
2 of 2 | |
---|---|
Drug Name | Tekturna |
PubMed Health | Aliskiren (By mouth) |
Drug Classes | Antihypertensive |
Drug Label | Tekturna contains aliskiren hemifumarate, a renin inhibitor, that is provided as tablets for oral administration. Aliskiren hemifumarate is chemically described as (2S,4S,5S,7S)-N-(2-carbamoyl-2-methylpropyl)-5-amino-4-hydroxy-2,7-diisopropyl-8-[4-me... |
Active Ingredient | Aliskiren hemifumarate |
Dosage Form | Tablet |
Route | Oral |
Strength | eq 150mg base; eq 300mg base |
Market Status | Prescription |
Company | Novartis |
Treatment of essential hypertension.
Treatment of essential hypertension.
Treatment of essential hypertension
Treatment of essential hypertension
C09XA02
C09XA02
C09XA02
C09XA02
RLD : Yes
TE Code : AB
Brand Name : TEKTURNA
Dosage Form : TABLET;ORAL
Dosage Strength : EQ 300MG BASE
Approval Date : 2007-03-05
Application Number : 21985
RX/OTC/DISCN : RX
RLD : Yes
TE Code : AB
RLD : Yes
TE Code :
ALISKIREN HEMIFUMARATE; HYDROCHLOROTHIAZIDE
Brand Name : TEKTURNA HCT
Dosage Form : TABLET;ORAL
Dosage Strength : EQ 150MG BASE;12.5MG **Federal Register determination that product was not discontinued or withdrawn for safety or effectiveness reasons**
Approval Date : 2008-01-18
Application Number : 22107
RX/OTC/DISCN : DISCN
RLD : Yes
TE Code :
RLD : Yes
TE Code :
ALISKIREN HEMIFUMARATE; HYDROCHLOROTHIAZIDE
Brand Name : TEKTURNA HCT
Dosage Form : TABLET;ORAL
Dosage Strength : EQ 150MG BASE;25MG **Federal Register determination that product was not discontinued or withdrawn for safety or effectiveness reasons**
Approval Date : 2008-01-18
Application Number : 22107
RX/OTC/DISCN : DISCN
RLD : Yes
TE Code :
RLD : Yes
TE Code :
ALISKIREN HEMIFUMARATE; HYDROCHLOROTHIAZIDE
Brand Name : TEKTURNA HCT
Dosage Form : TABLET;ORAL
Dosage Strength : EQ 300MG BASE;12.5MG **Federal Register determination that product was not discontinued or withdrawn for safety or effectiveness reasons**
Approval Date : 2008-01-18
Application Number : 22107
RX/OTC/DISCN : DISCN
RLD : Yes
TE Code :
RLD : Yes
TE Code :
Brand Name : TEKTURNA
Dosage Form : CAPSULE, PELLET;ORAL
Dosage Strength : EQ 37.5MG BASE
Approval Date : 2017-11-14
Application Number : 210709
RX/OTC/DISCN : DISCN
RLD : Yes
TE Code :
RLD : No
TE Code :
ALISKIREN HEMIFUMARATE; AMLODIPINE BESYLATE
Brand Name : TEKAMLO
Dosage Form : TABLET;ORAL
Dosage Strength : EQ 150MG BASE;EQ 10MG BASE
Approval Date : 2010-08-26
Application Number : 22545
RX/OTC/DISCN : DISCN
RLD : No
TE Code :
RLD : No
TE Code :
ALISKIREN HEMIFUMARATE; AMLODIPINE BESYLATE
Brand Name : TEKAMLO
Dosage Form : TABLET;ORAL
Dosage Strength : EQ 300MG BASE;EQ 5MG BASE
Approval Date : 2010-08-26
Application Number : 22545
RX/OTC/DISCN : DISCN
RLD : No
TE Code :
RLD : No
TE Code :
ALISKIREN HEMIFUMARATE; AMLODIPINE BESYLATE
Brand Name : TEKAMLO
Dosage Form : TABLET;ORAL
Dosage Strength : EQ 300MG BASE;EQ 10MG BASE
Approval Date : 2010-08-26
Application Number : 22545
RX/OTC/DISCN : DISCN
RLD : No
TE Code :
RLD : No
TE Code :
ALISKIREN HEMIFUMARATE; AMLODIPINE BESYLATE; HYDROCHLOROTHIAZIDE
Brand Name : AMTURNIDE
Dosage Form : TABLET;ORAL
Dosage Strength : EQ 150MG BASE;EQ 5MG BASE;12.5MG
Approval Date : 2010-12-21
Application Number : 200045
RX/OTC/DISCN : DISCN
RLD : No
TE Code :
Brand Name : ALISKIREN HEMIFUMARATE
Dosage Form : TABLET;ORAL
Dosage Strength : EQ 150MG BASE
Approval Date : 2019-03-22
Application Number : 206665
RX/OTC/DISCN : RX
RLD : No
TE Code : AB
Portfolio PDF
Product Web Link
Virtual Booth
Digital Content
Website
Corporate PDF
Regulatory Info :
Registration Country : Switzerland
Brand Name : Rasilez
Dosage Form : Filmtabl
Dosage Strength : 150mg
Packaging :
Approval Date :
Application Number :
Regulatory Info :
Registration Country : Switzerland
Portfolio PDF
Product Web Link
Virtual Booth
Digital Content
Website
Corporate PDF
Regulatory Info :
Registration Country : Switzerland
Brand Name : Rasilez
Dosage Form : Filmtabl
Dosage Strength : 150mg
Packaging :
Approval Date :
Application Number :
Regulatory Info :
Registration Country : Switzerland
Portfolio PDF
Product Web Link
Virtual Booth
Digital Content
Website
Corporate PDF
Regulatory Info :
Registration Country : Switzerland
Brand Name : Rasilez
Dosage Form : Filmtabl
Dosage Strength : 300mg
Packaging :
Approval Date :
Application Number :
Regulatory Info :
Registration Country : Switzerland
Portfolio PDF
Product Web Link
Virtual Booth
Digital Content
Website
Corporate PDF
Regulatory Info :
Registration Country : Switzerland
Brand Name : Rasilez
Dosage Form : Filmtabl
Dosage Strength : 300mg
Packaging :
Approval Date :
Application Number :
Regulatory Info :
Registration Country : Switzerland
Portfolio PDF
Product Web Link
Virtual Booth
Digital Content
Website
Corporate PDF
DRUG PRODUCT COMPOSITIONS
Related Excipient Companies
Excipients by Applications
Global Sales Information
Market Place
Patents & EXCLUSIVITIES
ABOUT THIS PAGE
A Aliskiren manufacturer is defined as any person or entity involved in the manufacture, preparation, processing, compounding or propagation of Aliskiren, including repackagers and relabelers. The FDA regulates Aliskiren manufacturers to ensure that their products comply with relevant laws and regulations and are safe and effective to use. Aliskiren API Manufacturers are required to adhere to Good Manufacturing Practices (GMP) to ensure that their products are consistently manufactured to meet established quality criteria.
click here to find a list of Aliskiren manufacturers with USDMF, JDMF, KDMF, CEP, GMP, COA and API Price related information on PhamaCompass.
A Aliskiren supplier is an individual or a company that provides Aliskiren active pharmaceutical ingredient (API) or Aliskiren finished formulations upon request. The Aliskiren suppliers may include Aliskiren API manufacturers, exporters, distributors and traders.
click here to find a list of Aliskiren suppliers with USDMF, JDMF, KDMF, CEP, GMP, COA and API Price related information on PharmaCompass.
A Aliskiren DMF (Drug Master File) is a document detailing the whole manufacturing process of Aliskiren active pharmaceutical ingredient (API) in detail. Different forms of Aliskiren DMFs exist exist since differing nations have different regulations, such as Aliskiren USDMF, ASMF (EDMF), JDMF, CDMF, etc.
A Aliskiren DMF submitted to regulatory agencies in the US is known as a USDMF. Aliskiren USDMF includes data on Aliskiren's chemical properties, information on the facilities and procedures used, and details about packaging and storage. The Aliskiren USDMF is kept confidential to protect the manufacturer’s intellectual property.
click here to find a list of Aliskiren suppliers with USDMF on PharmaCompass.
A Aliskiren written confirmation (Aliskiren WC) is an official document issued by a regulatory agency to a Aliskiren manufacturer, verifying that the manufacturing facility of a Aliskiren active pharmaceutical ingredient (API) adheres to the Good Manufacturing Practices (GMP) regulations of the importing country. When exporting Aliskiren APIs or Aliskiren finished pharmaceutical products to another nation, regulatory agencies frequently require a Aliskiren WC (written confirmation) as part of the regulatory process.
click here to find a list of Aliskiren suppliers with Written Confirmation (WC) on PharmaCompass.
National Drug Code is a comprehensive database maintained by the FDA that contains information on all drugs marketed in the US. This directory includes information about finished drug products, unfinished drug products, and compounded drug products, including those containing Aliskiren as an active pharmaceutical ingredient (API).
The FDA updates the NDC directory daily. The NDC numbers for Aliskiren API and other APIs are published in this directory by the FDA.
The NDC unfinished drugs database includes product listing information submitted for all unfinished drugs, such as active pharmaceutical ingredients (APIs), drugs intended for further processing and bulk drug substances for compounding.
Pharmaceutical companies that manufacture Aliskiren as an active pharmaceutical ingredient (API) must furnish the FDA with an updated record of all drugs that they produce, prepare, propagate, compound, or process for commercial distribution in the US at their facilities.
The NDC directory also contains data on finished compounded human drug products that contain Aliskiren and are produced by outsourcing facilities. While these outsourcing facilities are not mandated to assign a Aliskiren NDC to their finished compounded human drug products, they may choose to do so.
click here to find a list of Aliskiren suppliers with NDC on PharmaCompass.
Aliskiren Active pharmaceutical ingredient (API) is produced in GMP-certified manufacturing facility.
GMP stands for Good Manufacturing Practices, which is a system used in the pharmaceutical industry to make sure that goods are regularly produced and monitored in accordance with quality standards. The FDA’s current Good Manufacturing Practices requirements are referred to as cGMP or current GMP which indicates that the company follows the most recent GMP specifications. The World Health Organization (WHO) has its own set of GMP guidelines, called the WHO GMP. Different countries can also set their own guidelines for GMP like China (Chinese GMP) or the EU (EU GMP).
PharmaCompass offers a list of Aliskiren GMP manufacturers, exporters & distributors, which can be sorted by USDMF, JDMF, KDMF, CEP (COS), WC, API price, and more, enabling you to easily find the right Aliskiren GMP manufacturer or Aliskiren GMP API supplier for your needs.
A Aliskiren CoA (Certificate of Analysis) is a formal document that attests to Aliskiren's compliance with Aliskiren specifications and serves as a tool for batch-level quality control.
Aliskiren CoA mostly includes findings from lab analyses of a specific batch. For each Aliskiren CoA document that a company creates, the USFDA specifies specific requirements, such as supplier information, material identification, transportation data, evidence of conformity and signature data.
Aliskiren may be tested according to a variety of international standards, such as European Pharmacopoeia (Aliskiren EP), Aliskiren JP (Japanese Pharmacopeia) and the US Pharmacopoeia (Aliskiren USP).
LOOKING FOR A SUPPLIER?